Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CON, LIC

SpectraMedix and Foresight Health Solutions Partner for AI-Enabled Value-Based Payment Technologies, Championing Health Equity and Social Determinants


Collaboration Improves Healthcare Access, Equity, Quality and Savings Optimization for Value-Based Contracts

EAST WINDSOR, N.J., May 9, 2024 /PRNewswire/ -- SpectraMedix, a leading value-based contract analytics and provider enablement platform for health plans and health systems, announced today a strategic partnership with Foresight Health Solutions, a pioneer in AI-driven social determinants of health (SDoH) risk management and health equity analytics. A significant advancement in the industry, this partnership will offer unparalleled capabilities to care providers and health plans in predicting comprehensive health risks using SDoH and health disparity data. This partnership will accelerate the understanding of what is driving cost and outcomes for vulnerable populations, enabling organizations to achieve greater success in value-based care.

SpectraMedix's best-in-class technology enables health plans and health systems to analyze financial, quality, risk, utilization, and health equity information to understand value-based contract performance and identify opportunities for improvement. Foresight Health adds expertise in AI-enabled analysis of SDoH and care management data for risk identification, and to accurately pinpoint care interventions that would be most impactful in mitigating risks. The integration will provide a more complete picture of root-cause cost and health factors, improving healthcare access, equity, quality and savings across business lines to optimize value-based contracts and help providers deliver better, more informed care.

"Our partnership brings additional transparency around how social determinants of health impact risk, quality and shared savings for vulnerable populations such as Medicaid and Medicare," said SpectraMedix CEO Raj Lakhanpal, MD. "Empowering organizations with the right information at the right time to understand both medical and non-medical drivers of quality, risk and utilization is a gamechanger for value-based contract success."

"Our integration with SpectraMedix brings SDoH and care management data analytics and value-based payment analytics together in a way that mutually reinforce each other," said Ashish Abraham, CEO of Foresight Health Solutions. "Together, we provide deep insights that enhance the effectiveness and ROI of care delivery?ultimately improving the health of individuals and populations."

About SpectraMedix

SpectraMedix delivers the complete picture of value-based performance to drive operational excellence and accelerate performance improvement for health plans and health systems across the spectrum of value-based contracts. Our comprehensive, end-to-end platform empowers organizations with transparency into financial performance, quality, risk and utilization to help them establish trust with providers, maximize revenue and scale their value-based arrangements. 

About Foresight Health Solutions

Foresight Health Solutions provides community-based providers and health plans with AI-driven health equity, predictive risk and prescriptive care impact analytics by blending SDoH data with other standard data sources. Through our web-based analytics platform or through integrations with existing EMRs and care management systems, clients can optimize the ROI on value-based care management programs, while at the same time meaningfully reduce health disparities among vulnerable populations.

Media Contact:
Dylan Stump
9082512809
[email protected]

SOURCE SpectraMedix


These press releases may also interest you

at 04:45
ERS Genomics and IRBM Sign CRISPR/Cas9 License Agreement
ERS Genomics Limited (?ERS'), the CRISPR licensing Company, and IRBM, a leader in the field of drug discovery, today announced a non-exclusive CRISPR/Cas9 license agreement. The agreement grants IRBM access to ERS' CRISPR/Cas9 patent portfolio....

at 03:15
Cresilon Announces International Distribution Agreement for VETIGEL with Covetrus
Cresilon Inc. ("Cresilon"), a Brooklyn-based biotechnology company focused on haemostatic medical device technologies, today announced it has entered into a distribution agreement for its revolutionary haemostatic gel, VETIGEL®, to be sold directly...

at 02:30
New Research by Tea Advisory Panel Reveals That Three Quarters Of Brits Never Drink Tea Before A Workout Despite It Counting Towards Fluid Intake Recommendations
Ahead of International Tea Day - 21st May 2024  - and with summer inspiring more of us to get off the sofa to be active, a 2024 real-world research study1 reviewed by the tea science experts at the Tea Advisory Panel ? www.teaadvisorypanel.com -...

at 02:30
TREEFROG PRESENTS DATA FROM THEIR PARKINSON'S DISEASE CELL THERAPY PROGRAM AT THE 29TH WORLD CONGRESS ON PARKINSON'S DISEASE AND RELATED DISORDERS (IAPRD) IN LISBON
TreeFrog Therapeutics will participate for the first time at the IAPRD, to present data from their Parkinson's disease cell therapy program, which has demonstrated excellent results with full motor recovery at 16 weeks in preclinical studies.[1]...

at 02:20
Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis
Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis...

at 02:07
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Approval
GC Biopharma (006280. KS) and Novel Pharma announced that its jointly developed MPS IIIA 'GC1130A' treatment has received FDA IND approval....

More news about Health...


News published on and distributed by: